Fred has two decades of experience in the Pharmaceutical and Biotechnology industries.

For over 10 years, he worked at Pfizer both in the United States and Europe across Strategy, Business Development, and Portfolio Prioritization at the Corporate and at the Business Unit levels. After Pfizer, Fred became a senior member of the Corporate Strategy and Corporate Development team at Celgene, a leading global biotechnology company in cancer and immunology therapies. After four years at Celgene, he played a key role in the evaluation, transaction, and closing of the acquisition of the company by Bristol Myers Squibb. Fred then became the Senior Vice President of Global Business Development at Insmed, a commercial-stage and publicly traded biotech company focused on respiratory rare diseases.

Through his immersion in biotech companies, Fred realized that these organizations could greatly benefit from a more flexible way to leverage senior expertise in Business Development, Strategy, and Portfolio Prioritization. Propelled by this insight and by his desire to support innovation, Fred created a consulting practice to help leading biotechs achieve their strategic and partnering objectives and maximize the impact of their scientific breakthroughs on human health.

Fred received a Masters of Business Administration (MBA) from the Massachusetts Institute of Technology (MIT) and a Master of Electrical Engineering and Computer Science from Institut Polytechnique de Paris - Telecom Paris.